title: Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV).
abstract: Genetically engineered plants are economical platforms for the large-scale production of recombinant proteins and have been used over the last 21 years as models for oral vaccines against a wide variety of human infectious and autoimmune diseases with promising results. The main inherent advantages of this approach consist in the absence of purification needs and easy production and administration. One relevant infectious agent is the human immunodeficiency virus (HIV), since AIDS evolved as an alarming public health problem implicating very high costs for government agencies in most African and developing countries. The design of an effective and inexpensive vaccine able to limit viral spread and neutralizing the viral entry is urgently needed. Due to the limited efficacy of the vaccines assessed in clinical trials, new HIV vaccines able to generate broad immune profiles are a priority in the field. This review discusses the current advances on the topic of using plants as alternative expression systems to produce functional vaccine components against HIV, including antigens from Env, Gag and early proteins such as Tat and Nef. Ongoing projects of our group based on the expression of chimeric proteins comprising C4 and V3 domains from gp120, as an approach to elicit broadly neutralizing antibodies are mentioned. The perspectives of the revised approaches, such as the great need of assessing the oral immunogenicity and a detailed immunological characterization of the elicited immune responses, are also discussed.
authors.affiliation: Laboratorio de Biofarmacéuticos recombinantes, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosí 78210, Mexico. rosales.s@fcq.uaslp.mx
authors.forename: Sergio
authors.initials: S
authors.lastname: Rosales-Mendoza
authors.forename: Néstor
authors.initials: N
authors.lastname: Rubio-Infante
authors.forename: Dania O
authors.initials: DO
authors.lastname: Govea-Alonso
authors.forename: Leticia
authors.initials: L
authors.lastname: Moreno-Fierros
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage*; D000956:Antigens, Viral / Q000276:immunology*; D015683:Gene Products, gag / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D010944:Plants / Q000235:genetics / Q000378:metabolism*; D030821:Plants, Genetically Modified; D054299:env Gene Products, Human Immunodeficiency Virus / Q000276:immunology; D054311:nef Gene Products, Human Immunodeficiency Virus / Q000276:immunology; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D000956:Antigens, Viral; D015683:Gene Products, gag; D015699:HIV Envelope Protein gp120; D054299:env Gene Products, Human Immunodeficiency Virus; D054311:nef Gene Products, Human Immunodeficiency Virus; D054322:tat Gene Products, Human Immunodeficiency Virus